Cabaletta Bio, Inc. (CABA) FinancialsCABAFinancialCabaletta Bio, Inc.

Evaluating the bottom line, Cabaletta Bio, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -93.20%, provide a clear picture of how effectively CABA converts its operational activities into shareholder value.

In the context of the broader market, CABA competes directly with industry leaders such as VALN and SCTX. With a market capitalization of $466.25M, it holds a significant position in the sector. When comparing efficiency, CABA's gross margin of N/A stands against VALN's 9.60% and SCTX's N/A. Such benchmarking helps identify whether Cabaletta Bio, Inc. is trading at a premium or discount relative to its financial performance.

Cabaletta Bio has shown a 1-year change of +115.17% and a year-to-date change of +41.18%. However, it has reported consistent net income losses, with Q2 2026 showing a loss of $51 million. The current ratio is strong at 5.79, indicating good liquidity, but the company has a negative P/E ratio of -3.16, reflecting ongoing financial challenges.